Abstract 285P
Background
Adjuvant ET reduces breast cancer recurrence and increases overall survival among patients with early-stage ER+ breast cancer, however a suboptimal number of patients older than 65 years are included in the studies. This study aims to evaluate adherence to adjuvant ET and sexual dysfunction in women >65 years old with early breast cancer.
Methods
Women with a history of early-stage ER+ invasive carcinoma of the breast on adjuvant ET for at least 6 months were invited to participate. Adherence was assessed with Morisky Medication Adherence Scale (MMAS-8). Quality of life was assessed using EORTC QLQ C30 and BR-23 forms. Sexuality was assessed with the Female Sex Function Index questionnaire. Patients were stratified according to age <=65 years and > 65 years old. Qualitative variables were compared between groups using the Chi-square or exact Chi-square test and for quantitative variables the non-parametric Mann-Whitney test was used.
Results
From June 2021 to March 2024, 774 women from 15 Brazilian institutions were recruited. Mean age was 62 y.o, mean tumor size was 2.24 cm, mean duration of ET was 3.2y. About 191 patients (24.7%) were older than 65y, 69.6% of them were high adherent to ET and 70.7% had sexual dysfunction. In comparison with women <=65 y.o, older women were associated with private healthcare insurance (p=0.003), living with no partner (p < 0.0001), prior lumpectomy (p = 0.0017), prior sentinel node biopsy (p = 0.03), no prior chemotherapy (p < 0.0001), use of aromatase inhibitors (p < 0.0001) and use of concomitant medications (p < 0,0001). Patients older than 65 years were more associated with lower adherence (p = 0.0009), but there was no difference in sexual dysfunction in comparison with patients less than 65 y. Patients over 65 years had significantly higher scores for Emotional Functioning, Cognitive Functioning, Social Functioning, Body Image and Future Perspective domains of quality of life.
Conclusions
Patients older than 65 y.o had less aggressive treatments, many better domains in quality of life, but lower adherence to ET than patients aged up to 65 years. An important issue for womens’ health is sexual health and in this context, sexual dysfunction affects women besides age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
292P - Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR)
Presenter: Komal Jhaveri
Session: Poster session 14
293P - Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
Presenter: Luc Cabel
Session: Poster session 14
294P - Survival outcomes according to tumor-infiltrating lymphocytes and 21-gene recurrence score in ER+HER2- breast cancer
Presenter: Sung Gwe Ahn
Session: Poster session 14
295P - Long-term clinical outcomes and treatment strategy considerations by ER expression level in breast cancer
Presenter: Yumi Wanifuchi-Endo
Session: Poster session 14
296P - Investigating survival by breast cancer molecular subtype in Australia: A population-based study
Presenter: Larissa Vaz-Goncalves
Session: Poster session 14
297P - Real-world data on prognostication of early stage breast cancer patients using CanAssist Breast- first immunohistochemistry based prognostic test developed and validated on Asians
Presenter: Vashista Maniar
Session: Poster session 14
Resources:
Abstract
298P - Enhancing prognostic accuracy for breast adenoid cystic carcinoma using machine learning models
Presenter: Sakhr Alshwayyat
Session: Poster session 14
Resources:
Abstract
299P - Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer
Presenter: Jitnarong Karnmanee
Session: Poster session 14
300P - Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up
Presenter: Julia Tutzauer
Session: Poster session 14
301P - Changes in lipid-levels following aromatase inhibitor treatment in early postmenopausal breast cancer
Presenter: Marie Lund
Session: Poster session 14